Thimerosal-Preserved Hepatitis B Vaccine and Hyperkinetic Syndrome of Childhood
Abstract
:1. Introduction
2. Methods
2.1. The Database from the Vaccine Safety Datalink and Study Approval
2.2. How the Population at Risk Was Determined
2.3. How Cases Were Determined
2.4. How Controls Were Determined
2.5. Exposure to HepB Vaccine
2.6. Statistical Analyses
3. Results
4. Discussion
Study Limitations and Strengths
5. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
References
- International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Available online: http://www.cdc.gov/nchs/icd/icd9cm.htm (accessed on 1 March 2016).
- American Psychiatric Association. Diagnostic criteria for autistic disorder. In Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; American Psychiatric Publishing: Washington, DC, USA, 2013. [Google Scholar]
- Reiersen, A.M.; Todd, R.D. Co-occurrence of ADHD and autism spectrum disorders: Phenomenology and treatment. Expert Rev. Neurother. 2008, 8, 657–669. [Google Scholar] [CrossRef] [PubMed]
- Grzadzinski, R.; Di Martino, A.; Brady, E.; Mairena, M.A.; O’Neale, M.; Petkova, E.; Lord, C.; Castellanos, F.X. Examining autistic traits in children with ADHD: Does the autism spectrum extend to ADHD? J. Autism Dev. Disord. 2011, 41, 1178–1191. [Google Scholar] [CrossRef] [PubMed]
- Attention-Deficit/Hyperactivity Disorder (ADHD)—New Data: Medication and Behavior Treatment. Available online: http://www.cdc.gov/ncbddd/adhd/data.html (accessed on 8 August 2013).
- Arnold, L.E. Sex differences in ADHD: Conference summary. J. Abnorm. Child Psychol. 1996, 24, 555–569. [Google Scholar] [CrossRef] [PubMed]
- Culpepper, L.; Fried, R. Attention-deficit/hyperactivity disorder in a chronic care paradigm. Postgrad. Med. 2013, 125, 78–86. [Google Scholar] [CrossRef] [PubMed]
- Tomasi, D.; Volkow, N.D. Abnormal functional connectivity in children with attention-deficit/hyperactivity disorder. Biol. Psychiatry 2012, 71, 443–450. [Google Scholar] [CrossRef] [PubMed]
- Polanczyk, G.; de Lima, M.S.; Horta, B.L.; Biederman, J.; Rohde, L.A. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am. J. Psychiatry 2007, 164, 942–948. [Google Scholar] [CrossRef] [PubMed]
- Boyle, C.A.; Boulet, S.; Schieve, L.A.; Cohen, R.A.; Blumberg, S.J.; Yeargin-Allsopp, M.; Visser, S.; Kogan, M.D. Trends in the prevalence of developmental disabilities in US children, 1997–2008. Pediatrics 2011, 127, 1034–1042. [Google Scholar] [CrossRef] [PubMed]
- Kalia, M. Brain development: Anatomy, connectivity, adaptive plasticity, and toxicity. Metab. Clin. Exp. 2008, 57, S2–S5. [Google Scholar] [CrossRef] [PubMed]
- Kern, J.K.; Geier, D.A.; Sykes, L.K.; Geier, M.R.; Deth, R.C. Are ASD and ADHD a continuum? A comparison of pathophysiological similarities between the disorders. J. Atten. Disord. 2012. [Google Scholar] [CrossRef] [PubMed]
- Eubig, P.A.; Aguiar, A.; Schantz, S.L. Lead and PCBs as risk factors for attention deficit/hyperactivity disorder. Environ. Health Perspect. 2010, 118, 1654–1667. [Google Scholar] [CrossRef] [PubMed]
- Ha, M.; Kwon, H.J.; Lim, M.H.; Jee, Y.K.; Hong, Y.C.; Leem, J.H.; Sakong, J.; Bae, J.M.; Hong, S.J.; Roh, Y.M.; et al. Low blood levels of lead and mercury and symptoms of attention deficit hyperactivity in children: A report of the children’s health and environment research (CHEER). Neurotoxicology 2009, 30, 31–36. [Google Scholar] [CrossRef] [PubMed]
- Nicolescu, R.; Petcu, C.; Cordeanu, A.; Fabritius, K.; Schlumpf, M.; Krebs, R.; Krämer, U.; Winneke, G. Environmental exposure to lead, but not other neurotoxic metals, relates to core elements of ADHD in Romanian children: Performance and questionnaire data. Environ. Res. 2010, 110, 476–483. [Google Scholar] [CrossRef] [PubMed]
- Boucher, O.; Jacobson, S.W.; Plusquellec, P.; Dewailly, E.; Ayotte, P.; Forget-Dubois, N.; Jacobson, J.L.; Muckle, G. Prenatal methylmercury, postnatal lead exposure, and evidence of attention deficit/hyperactivity disorder among Inuit children in Arctic Quebec. Environ. Health Perspect. 2012, 120, 1456–1461. [Google Scholar] [CrossRef] [PubMed]
- Young, H.A.; Geier, D.A.; Geier, M.R. Thimerosal exposure in infants and neurodevelopmental disorders: An assessment of computerized medical records in the Vaccine Safety Datalink. J. Neurol. Sci. 2008, 271, 110–118. [Google Scholar] [CrossRef] [PubMed]
- Geier, D.A.; Geier, M.R. A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: A follow-up analysis. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2005, 11, CR160–CR170. [Google Scholar]
- Geier, D.A.; Hooker, B.S.; Kern, J.K.; King, P.G.; Sykes, L.K.; Geier, M.R. A two-phase study evaluating the relationship between Thimerosal-containing vaccine administration and the risk for an autism spectrum disorder diagnosis in the United States. Transl. Neurodegener. 2013, 2, 25. [Google Scholar] [CrossRef] [PubMed]
- Heron, J.; Golding, J.; Team, A.S. Thimerosal exposure in infants and developmental disorders: A prospective cohort study in the United Kingdom does not support a causal association. Pediatrics 2004, 114, 577–583. [Google Scholar] [CrossRef] [PubMed]
- Centers for Disease Control and Prevention (CDC). Vaccine Safety Datalink (VSD). Available online: http://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/accessing-data.html (accessed on 3 March 2016).
- Ellenberg, S.S.; Braun, M.M. Monitoring the safety of vaccines: Assessing the risks. Drug Saf. 2002, 25, 145–152. [Google Scholar] [CrossRef] [PubMed]
- Varricchio, F.; Iskander, J.; Destefano, F.; Ball, R.; Pless, R.; Braun, M.M.; Chen, R.T. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr. Infect. Dis. J. 2004, 23, 287–294. [Google Scholar] [CrossRef] [PubMed]
- Iskander, J.; Pool, V.; Zhou, W.; English-Bullard, R.; Team, V. Data mining in the US using the Vaccine Adverse Event Reporting System. Drug Saf. 2006, 29, 375–384. [Google Scholar] [CrossRef] [PubMed]
- Van Buren, R.C. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm. Rep. 1991, 40, 1–25. [Google Scholar]
- Kern, J.K.; Haley, B.E.; Geier, D.A.; Sykes, L.K.; King, P.G.; Geier, M.R. Thimerosal exposure and the role of sulfation chemistry and thiol availability in autism. Int. J. Environ. Res. Public Health 2013, 10, 3771–3800. [Google Scholar] [CrossRef] [PubMed]
- Dorea, J.G. Low-dose mercury exposure in early life: Relevance of thimerosal to fetuses, newborns and infants. Curr. Med. Chem. 2013, 20, 4060–4069. [Google Scholar] [CrossRef] [PubMed]
- Burbacher, T.M.; Shen, D.D.; Liberato, N.; Grant, K.S.; Cernichiari, E.; Clarkson, T. Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal. Environ. Health Perspect. 2005, 113, 1015–1021. [Google Scholar] [CrossRef] [PubMed]
- Rodrigues, J.L.; Serpeloni, J.M.; Batista, B.L.; Souza, S.S.; Barbosa, F., Jr. Identification and distribution of mercury species in rat tissues following administration of thimerosal or methylmercury. Arch. Toxicol. 2010, 84, 891–896. [Google Scholar] [CrossRef] [PubMed]
- Zimmermann, L.T.; Santos, D.B.; Naime, A.A.; Leal, R.B.; Dorea, J.G.; Barbosa, F., Jr.; Aschner, M.; Rocha, J.B.; Farina, M. Comparative study on methyl- and ethylmercury-induced toxicity in C6 glioma cells and the potential role of LAT-1 in mediating mercurial-thiol complexes uptake. Neurotoxicology 2013, 38, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Pichichero, M.E.; Gentile, A.; Giglio, N.; Umido, V.; Clarkson, T.; Cernichiari, E.; Zareba, G.; Gotelli, C.; Gotelli, M.; Yan, L.; et al. Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines. Pediatrics 2008, 121, e208–e214. [Google Scholar] [CrossRef] [PubMed]
- Pichichero, M.E.; Gentile, A.; Giglio, N.; Alonso, M.M.; Fernandez Mentaberri, M.V.; Zareba, G.; Clarkson, T.; Gotelli, C.; Gotelli, M.; Yan, L.; et al. Mercury levels in premature and low birth weight newborn infants after receipt of thimerosal-containing vaccines. J. Pediatr. 2009, 155, 495–499. [Google Scholar] [CrossRef] [PubMed]
- Stajich, G.V.; Lopez, G.P.; Harry, S.W.; Sexson, W.R. Iatrogenic exposure to mercury after hepatitis B vaccination in preterm infants. J. Pediatr. 2000, 136, 679–681. [Google Scholar] [CrossRef] [PubMed]
- Marques, R.C.; Dorea, J.G.; Fonseca, M.F.; Bastos, W.R.; Malm, O. Hair mercury in breast-fed infants exposed to thimerosal-preserved vaccines. Eur. J. Pediatr. 2007, 166, 935–941. [Google Scholar] [CrossRef] [PubMed]
- Castoldi, A.F.; Coccini, T.; Manzo, L. Neurotoxic and molecular effects of methylmercury in humans. Rev. Environ. Health 2003, 18, 19–31. [Google Scholar] [CrossRef] [PubMed]
- Vogel, D.G.; Margolis, R.L.; Mottet, N.K. The effects of methyl mercury binding to microtubules. Toxicol. Appl. Pharmacol. 1985, 80, 473–486. [Google Scholar] [CrossRef]
- Choi, B.H.; Cho, K.H.; Lapham, L.W. Effects of methylmercury on human fetal neurons and astrocytes in vitro: A time-lapse cinematographic, phase and electron microscopic study. Environ. Res. 1981, 24, 61–74. [Google Scholar] [CrossRef]
- Leong, C.C.; Syed, N.I.; Lorscheider, F.L. Retrograde degeneration of neurite membrane structural integrity of nerve growth cones following in vitro exposure to mercury. Neuroreport 2001, 12, 733–737. [Google Scholar] [CrossRef] [PubMed]
- Jacquin, M.F.; Barcia, M.; Rhoades, R.W. Structure-function relationships in rat brainstem subnucleus interpolaris: IV. Projection neurons. J. Comp. Neurol. 1989, 282, 45–62. [Google Scholar] [CrossRef] [PubMed]
- Taylor, W.R. Response properties of long-range axon-bearing amacrine cells in the dark-adapted rabbit retina. Vis. Neurosci. 1996, 13, 599–604. [Google Scholar] [CrossRef] [PubMed]
- Pamphlett, R.; Png, F.Y. Shrinkage of motor axons following systemic exposure to inorganic mercury. J. Neuropathol. Exp. Neurol. 1998, 57, 360–366. [Google Scholar] [CrossRef] [PubMed]
- Stankovic, R.K.; Shingde, M.; Cullen, K.M. The experimental toxicology of metallic mercury on the murine peripheral motor system: A novel method of assessing axon calibre spectra using the phrenic nerve. J. Neurosci. Methods 2005, 147, 114–125. [Google Scholar] [CrossRef] [PubMed]
- Mitchell, J.; Gallagher, P.J. Peripheral neuropathy following intraneural injection of mercury compounds. Arch. Toxicol. 1980, 46, 257–264. [Google Scholar] [CrossRef] [PubMed]
- Barttfeld, P.; Wicker, B.; Cukier, S.; Navarta, S.; Lew, S.; Sigman, M. A big-world network in ASD: Dynamical connectivity analysis reflects a deficit in long-range connections and an excess of short-range connections. Neuropsychologia 2011, 49, 254–263. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; Zhu, C.; He, Y.; Zang, Y.; Cao, Q.; Zhang, H.; Zhong, Q.; Wang, Y. Altered small-world brain functional networks in children with attention-deficit/hyperactivity disorder. Hum. Brain Mapp. 2009, 30, 638–649. [Google Scholar] [CrossRef] [PubMed]
- Uddin, L.Q.; Supekar, K.; Menon, V. Typical and atypical development of functional human brain networks: Insights from resting-state FMRI. Front. Syst. Neurosci. 2010, 4, 21. [Google Scholar] [CrossRef] [PubMed]
- Fair, D.A.; Dosenbach, N.U.; Church, J.A.; Cohen, A.L.; Brahmbhatt, S.; Miezin, F.M.; Barch, D.M.; Raichle, M.E.; Petersen, S.E.; Schlaggar, B.L. Development of distinct control networks through segregation and integration. PNAS 2007, 104, 13507–13512. [Google Scholar] [CrossRef] [PubMed]
- Geier, D.A.; Hooker, B.S.; Kern, J.K.; King, P.G.; Sykes, L.K.; Geier, M.R. A dose-response relationship between organic mercury exposure from Thimerosal-containing vaccines and neurodevelopmental disorders. Int. J. Environ. Res. Public Health 2014, 11, 9156–9170. [Google Scholar] [CrossRef] [PubMed]
- Yoshimasu, K.; Kiyohara, C.; Takemura, S.; Nakai, K. A meta-analysis of the evidence of the impact of prenatal and early infancy exposures to mercury on autism and attention deficit/hyperactivity disorder in the childhood. Neurotoxicology 2014, 44, 121–131. [Google Scholar] [CrossRef] [PubMed]
- Andrews, N.; Miller, E.; Grant, A.; Stowe, J.; Osborne, V.; Taylor, B. Thimerosal exposure in infants and developmental disorders: A retrospective cohort study in the United Kingdom does not support a causal association. Pediatrics 2004, 114, 584–591. [Google Scholar] [CrossRef] [PubMed]
- Verstraeten, T.; Davis, R.L.; DeStefano, F.; Lieu, T.A.; Rhodes, P.H.; Black, S.B.; Shinefield, H.; Chen, R.T.; Vaccine Safety Datalink Team. Safety of thimerosal-containing vaccines: A two-phased study of computerized health maintenance organization databases. Pediatrics 2003, 112, 1039–1048. [Google Scholar] [PubMed]
- Laks, D.R. Assessment of chronic mercury exposure within the U.S. population, National Health and Nutrition Examination Survey, 1999–2006. Biometals 2009, 22, 1103–1114. [Google Scholar] [CrossRef] [PubMed]
- Geier, M.R.; Geier, D.A. The state of polio vaccination in the world: The case for continuing routine vaccination. Toxicol. Mech. Methods 2002, 12, 221–228. [Google Scholar] [CrossRef] [PubMed]
Year of Birth | Frequency of Cases Diagnosed with HKSoC | Percent of Cases Diagnosed with HKSoC | Frequency of Controls | Percent of Controls |
---|---|---|---|---|
1991 | 402 | 23.21 | 6130 | 29.78 |
1992 | 420 | 24.25 | 9463 | 45.97 |
1993 | 431 | 24.88 | 4991 | 24.25 |
1994 | 235 | 13.57 | - | - |
1995 | 133 | 7.68 | - | - |
1996 | 63 | 3.64 | - | - |
1997 | 24 | 1.39 | - | - |
1998 | * | * | - | - |
1999 | * | * | - | - |
2000 | * | * | - | - |
Group Examined | Number Diagnosed with HKSoC (%) | Number without a Diagnosis of HKSoC (%) | Odds Ratio (95% CI) | p-value |
---|---|---|---|---|
Analysis I | ||||
12.5 µg Hg exposure within 1st month | 549 (36.97) | 5921 (28.77) | 1.45 (1.30–1.62) | <0.001 |
0 µg Hg exposure within 1st month | 936 (63.03) | 14,663 (71.23) | ||
Analysis II | ||||
25 µg Hg exposure within first 2 months | 550 (37.39) | 5930 (29.48) | 1.43 (1.28–1.59) | <0.001 |
0 µg Hg exposure within first 2 months | 921 (62.61) | 14,185 (70.52) | ||
Analysis III | ||||
37.5 µg Hg exposure within first 6 months | 112 (76.71) | 725 (42.18) | 4.51 (3.04–6.71) | <0.001 |
0 µg Hg exposure within first 6 months | 34 (23.29) | 994 (57.82) |
Group Examined | Number Diagnosed with HKSoC (%) | Number without a Diagnosis of HKSoC (%) | Odds Ratio (95% CI) | p-value |
---|---|---|---|---|
Analysis IV | ||||
12.5 µg Hg exposure within 1st month | 424 (36.61) | 2943 (28.56) | 1.44 (1.27–1.64) | <0.001 |
0 µg Hg exposure within 1st month | 734 (63.39) | 7360 (71.44) | ||
Analysis V | ||||
25 µg Hg exposure within first 2 months | 425 (36.99) | 2947 (29.31) | 1.42 (1.25–1.61) | <0.001 |
0 µg Hg exposure within first 2 months | 724 (63.01) | 7109 (70.69) | ||
Analysis VI | ||||
37.5 µg Hg exposure within first 6 months | 90 (76.92) | 353 (42.22) | 4.56 (2.90–7.16) | <0.001 |
0 µg Hg exposure within first 6 months | 27 (23.08) | 483 (57.78) |
Group Examined | Number Diagnosed with HKSoC (%) | Number without a Diagnosis of HKSoC (%) | Odds Ratio (95% CI) | p-value |
---|---|---|---|---|
Analysis VII | ||||
12.5 µg Hg exposure within 1st month | 125 (38.23) | 2978 (28.97) | 1.52 (1.21–1.90) | <0.001 |
0 µg Hg exposure within 1st month | 202 (61.77) | 7303 (71.03) | ||
Analysis VIII | ||||
25 µg Hg exposure within first 2 months | 125 (38.82) | 2983 (29.66) | 1.51 (1.2–1.89) | <0.001 |
0 µg Hg exposure within first 2 months | 197 (61.18) | 7076 (70.34) | ||
Analysis IX | ||||
37.5 µg Hg exposure within first 6 months | 22 (75.86) | 372 (42.13) | 4.32 (1.83–10.21) | <0.001 |
0 µg Hg exposure within first 6 months | 7 (24.14) | 511 (57.87) |
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Geier, D.A.; Kern, J.K.; Hooker, B.S.; Sykes, L.K.; Geier, M.R. Thimerosal-Preserved Hepatitis B Vaccine and Hyperkinetic Syndrome of Childhood. Brain Sci. 2016, 6, 9. https://doi.org/10.3390/brainsci6010009
Geier DA, Kern JK, Hooker BS, Sykes LK, Geier MR. Thimerosal-Preserved Hepatitis B Vaccine and Hyperkinetic Syndrome of Childhood. Brain Sciences. 2016; 6(1):9. https://doi.org/10.3390/brainsci6010009
Chicago/Turabian StyleGeier, David A., Janet K. Kern, Brian S. Hooker, Lisa K. Sykes, and Mark R. Geier. 2016. "Thimerosal-Preserved Hepatitis B Vaccine and Hyperkinetic Syndrome of Childhood" Brain Sciences 6, no. 1: 9. https://doi.org/10.3390/brainsci6010009
APA StyleGeier, D. A., Kern, J. K., Hooker, B. S., Sykes, L. K., & Geier, M. R. (2016). Thimerosal-Preserved Hepatitis B Vaccine and Hyperkinetic Syndrome of Childhood. Brain Sciences, 6(1), 9. https://doi.org/10.3390/brainsci6010009